Φορτώνει......
Where are we going with CML research?
The introduction of Abl tyrosine kinase inhibitors (TKI; that is, imatinib, dasatinib and nilotinib) as front-line therapy completely changed the course of chronic myelogenous leukemia (CML) to the point that most of the TKI-responsive newly diagnosed CML patients can be considered ‘clinically'...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Leukemia Suppl |
|---|---|
| Κύριος συγγραφέας: | |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Nature Publishing Group
2012
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4851207/ https://ncbi.nlm.nih.gov/pubmed/27175251 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/leusup.2012.26 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|